Search hospitals > Ohio > Barberton
Summa Health System - Barberton Campus
Claim this profileBarberton, Ohio 44203
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Prostate Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
121 reported clinical trials
2 medical researchers
Summary
Summa Health System - Barberton Campus is a medical facility located in Barberton, Ohio. This center is recognized for care of Breast Cancer, Cancer, Prostate Cancer, Lung Cancer, Adenocarcinoma and other specialties. Summa Health System - Barberton Campus is involved with conducting 121 clinical trials across 174 conditions. There are 2 research doctors associated with this hospital, such as Bradley T. Clifford and Desiree E. Doncals.Area of expertise
1Breast Cancer
Global LeaderHER2 negative
ER positive
PR positive
2Cancer
Global LeaderStage III
p16 positive
p16 negative
Top PIs
Bradley T. CliffordSumma Health System - Akron Campus1 year of reported clinical research
Studies Cancer
Studies Breast Cancer
17 reported clinical trials
38 drugs studied
Desiree E. DoncalsSumma Health System - Akron Campus3 years of reported clinical research
Studies Cancer
Studies Breast Cancer
7 reported clinical trials
34 drugs studied
Clinical Trials running at Summa Health System - Barberton Campus
Breast Cancer
Prostate Cancer
Oropharyngeal Carcinoma
Squamous Cell Carcinoma
Cancer
Oral Squamous Cell Carcinoma
Recurrence
Oropharyngeal Cancer
Laryngeal Squamous Cell Carcinoma
Prostate Adenocarcinoma
Hormone Therapy with or without Radiation
for Breast Cancer
This study is evaluating whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Summa Health System - Barberton Campus?
Summa Health System - Barberton Campus is a medical facility located in Barberton, Ohio. This center is recognized for care of Breast Cancer, Cancer, Prostate Cancer, Lung Cancer, Adenocarcinoma and other specialties. Summa Health System - Barberton Campus is involved with conducting 121 clinical trials across 174 conditions. There are 2 research doctors associated with this hospital, such as Bradley T. Clifford and Desiree E. Doncals.